Wakefit Innovations' IPO saw a subscription of 2.52 times, with strong interest from retail and qualified institutional investors. Meanwhile, Corona Remedies' pharmaceutical IPO was heavily oversubscribed at 137.04 times, driven by significant demand from qualified institutional and non-institutional investors.

See Full Page